Skip to main content

LB Pharmaceuticals Inc

corporate_fare Company Profile

LB Pharmaceuticals Inc

LBRX·NASDAQ·Life Sciences·CIK 0001691082

LB PHARMACEUTICALS INC is a late-stage biopharmaceutical company focused on developing new treatments for various neuropsychiatric disorders, including schizophrenia, bipolar depression, and as an add-on treatment for major depressive disorder. The company is developing a pipeline centered on its main product candidate, LB-102. LB-102 is currently in late-stage clinical development for schizophrenia and bipolar depression. The company also plans to conduct a Phase 2 clinical trial for LB-102 as an adjunctive treatment in major depressive disorder (MDD). LB-102 is a new chemical entity and a methylated version of amisulpride. Amisulpride is a second-generation antipsychotic drug approved in over 50 countries, but not in the United States, due to regulatory requirements and patent coverage issues. Amisulpride has been widely used in clinical practice since its initial approval in France in the 1980s, with at least two million monthly prescriptions in 2023 across a subset of 16 continental European countries. Data from these European prescriptions indicate that approximately 60% are for schizophrenia and schizoaffective disorders, approximately 20% for mood disorders, approximately 14% for anxiety, and the rest for other conditions. LB-102 was designed to improve upon amisulpride, aiming for a distinct therapeutic profile and strong intellectual property protection. The company believes that LB-102's mechanism of action, results from its recently completed Phase 2 trial (NOVA-1) in acute schizophrenia, and the existing clinical experience with amisulpride support its continued development for both psychosis and mood disorders.

LB Pharmaceuticals Inc (NASDAQ:LBRX) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 24 items for LBRX at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-06, rated 7/10. Across its 20 most recent items scored 7 or higher, the top rating is 9/10, with 11 rated 8 or above. Recent SEC coverage for LBRX spans 10-Q, 8-K, S-3ASR, 4.

Recent high-impact activity:

  • Q3 Loss of $1.79 a Share Misses Consensus as R&D Spending Climbs
  • LB Pharmaceuticals Q3 Loss Widens to $59.1M as Material Weaknesses Remain Unremediated
  • LB Pharmaceuticals Posts $59.1M Q3 Loss; $403.8M Cash Funds Operations Past Q2 2029
  • LB Pharma Files $200M ATM and Registers 8.5M PIPE Shares for Resale
  • LB Pharma Q2 Loss Widens on Trial Costs; Material Weaknesses Persist; $150M Placement at Discount

Financial Snapshot

Fiscal year ended December 31, 2025
Net Income
-$25.2M
Diluted EPS
-$3.13
Op. Cash Flow
-$35.21M
Free Cash Flow
-$35.26M
Cash & Equivalents
$250.17M
Debt / Equity
0.00×
Shares Outstanding
25.3M sh
Source: 10-K · filed 2026-03-26 · accession 0001193125-26-126368

Short Interest & Short Volume

17.98 days to cover

FINRA reported short interest of 6,199,068 shares in LBRX as of the October 30, 2026 settlement, a 11.4% increase from the prior period — about 18.0 days to cover at its recent average daily volume. On November 20, 2026, 56.1% of LBRX volume reported to FINRA trade-reporting facilities was marked short.

Short interest (bi-monthly positions)6,199,068 shares as of October 30, 2026
Change vs prior period▲ 11.4%
Days to cover17.98 at avg daily volume of 344,721
Daily short volume (FINRA facilities)56.1% of 108,838 shares on November 20, 2026
5-day average short volume59.0%

Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.

Dilution Risk

Moderate risk

Filing-implied dilution signals for LBRX, detected from its recent SEC filings · based on capital-structure filings through 2026-10-01.

ATM program1 shelf registration

$200M ATM Program Launched · 8.49M PIPE Shares Registered for Resale

A filing-implied signal, not a realized share count. How Wiseek tracks dilution →

Browse all tickers starting with L →
$38.85
52-week range · as of 2026-11-05 $14.32 – $50.16
Market cap
$1.26B
Volume
302.9K (0.8× avg)
3-mo avg 399.1K
Live data · 2026-11-22 12:42 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed LBRX - Latest Insights

LBRX
Nov 05, 2026, 8:01 PM EST
Source: Reuters
Importance Score:
7
Price at Filing: $38.09
Real-time Price: $38.85 info
Change: +$0.760 (+2%) info
Market Cap: $1.257B info
LBRX
Nov 05, 2026, 4:32 PM EST
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $38.09
Real-time Price: $38.85 info
Change: +$0.760 (+2%) info
Market Cap: $1.257B info
LBRX
Nov 05, 2026, 4:16 PM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $38.09
Real-time Price: $38.85 info
Change: +$0.760 (+2%) info
Market Cap: $1.257B info
LBRX
Oct 01, 2026, 4:05 PM EDT
Filing Type: S-3ASR
Importance Score:
7
Price at Filing: $37.28
Real-time Price: $38.85 info
Change: +$1.57 (+4%) info
Market Cap: $1.257B info
LBRX
Aug 11, 2026, 8:10 AM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $46.76
Real-time Price: $38.85 info
Change: -$7.91 (-17%) info
Market Cap: $1.257B info
LBRX
Aug 11, 2026, 8:05 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $46.76
Real-time Price: $38.85 info
Change: -$7.91 (-17%) info
Market Cap: $1.257B info
LBRX
Aug 11, 2026, 8:00 AM EDT
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $46.76
Real-time Price: $38.85 info
Change: -$7.91 (-17%) info
Market Cap: $1.257B info
LBRX
Aug 03, 2026, 7:28 PM EDT
Filing Type: 4
Importance Score:
7
Price at Filing: $42.84
Real-time Price: $38.85 info
Change: -$3.99 (-9%) info
Market Cap: $1.257B info
LBRX
Jul 29, 2026, 8:05 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $35.44
Real-time Price: $38.85 info
Change: +$3.41 (+10%) info
Market Cap: $1.257B info
LBRX
Jul 29, 2026, 8:03 AM EDT
Source: Dow Jones Newswires
Importance Score:
8
Price at Filing: $33.62
Real-time Price: $38.85 info
Change: +$5.23 (+16%) info
Market Cap: $1.257B info
LBRX
Jul 22, 2026, 8:14 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $33.00
Real-time Price: $38.85 info
Change: +$5.85 (+18%) info
Market Cap: $1.257B info
LBRX
Jun 10, 2026, 4:16 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $28.39
Real-time Price: $38.85 info
Change: +$10.46 (+37%) info
Market Cap: $1.257B info
LBRX
May 12, 2026, 4:41 PM EDT
Source: Wiseek News
Importance Score:
7
Price at Filing: $31.13
Real-time Price: $38.85 info
Change: +$7.72 (+25%) info
Market Cap: $1.257B info
LBRX
May 12, 2026, 4:31 PM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $31.13
Real-time Price: $38.85 info
Change: +$7.72 (+25%) info
Market Cap: $1.257B info
LBRX
May 12, 2026, 4:05 PM EDT
Source: GlobeNewswire
Importance Score:
9
Price at Filing: $31.13
Real-time Price: $38.85 info
Change: +$7.72 (+25%) info
Market Cap: $1.257B info
LBRX
Apr 23, 2026, 4:06 PM EDT
Filing Type: DEF 14A
Importance Score:
8
Price at Filing: $30.78
Real-time Price: $38.85 info
Change: +$8.08 (+26%) info
Market Cap: $1.257B info
LBRX
Apr 14, 2026, 4:46 PM EDT
Filing Type: 424B3
Importance Score:
8
Price at Filing: $26.57
Real-time Price: $38.85 info
Change: +$12.28 (+46%) info
Market Cap: $1.257B info
LBRX
Apr 06, 2026, 4:05 PM EDT
Filing Type: S-1
Importance Score:
8
Price at Filing: $26.94
Real-time Price: $38.85 info
Change: +$11.91 (+44%) info
Market Cap: $1.257B info
LBRX
Mar 26, 2026, 4:07 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $24.97
Real-time Price: $38.85 info
Change: +$13.88 (+56%) info
Market Cap: $1.257B info
LBRX
Mar 26, 2026, 4:05 PM EDT
Source: GlobeNewswire
Importance Score:
9
Price at Filing: $24.97
Real-time Price: $38.85 info
Change: +$13.88 (+56%) info
Market Cap: $1.257B info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets